Why a cutting-edge cancer cell therapy company picked Sacramento for a key manufacturing site

The company's precision cell therapy for blood cancers is in a late-stage clinical trial, so the decision to expand manufacturing is a risky but needed one, the CEO said, given high demand and potential manufacturing bottlenecks.